Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial - Concepedia

Concepedia

Publication | Open Access

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

DOI Full Paper Access

76

Citations

24

References

2023

Year

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths,

The Lancet Oncology

Abstract

UK National Institute for Health and Care Research.

References

	Year	Citations

Page 1